MEDIPOST obtained a patent for its technology used for developing a cord blood stem cell-based Alzheimer’s disease treatment drug in the US.

The title of this patent is ‘Composition containing human umbilical cord blood-derived mesenchymal stem for inducing’.

MEDIPOST plans to use this technology to its Alzheimer’s disease treatment drug ‘NEUROSTEM^®’ currently being developed.

MEDIPOST already has a similar patent in Korea, China, Hong Kong, Singapore, Japan, UK, France, Germany, Italy, Spain, Switzerland, Australia and Mexico.